Diabetic Ketoacidosis Management and Treatment Outcome at Medical Ward of Shashemene Referral Hospital, Ethiopia: A Retrospective Study

Getu Melesie Taye1, Amente Jorise Bacha2, Fetene Abeje Taye3, Mohammed Husse Bule3 and Gosaye Mekonen Tefera2.

1Department of Pharmacy, Pharmacology Unit, Ambo University, Ambo, Ethiopia. 2Department of Pharmacy, Clinical Pharmacy Unit, Ambo University, Ambo, Ethiopia. 3Department of Pharmacy, Medicinal Chemistry Unit, Ambo University, Ambo, Ethiopia.

ABSTRACT

BACKGROUND: Diabetic Ketoacidosis (DKA) is the most common and yet potentially life-threatening acute complication of diabetes that progresses rapidly to death and requires immediate medical intervention.

OBJECTIVE: To assess the DKA management and treatment outcome/in-hospital mortality and its predictors among hospitalized patients with DKA at the Medical ward of Shashemene Referral Hospital (SRH).

METHOD: A retrospective study was conducted at the Medical Ward of SRH from 01 February 2015 to 31 January 2017. A systematic random sampling technique was used to select study subjects based on the inclusion criteria. Thus, of 236 reviewed charts, only 225 patients with DKA fulfilled inclusion criteria. Treatment outcome was considered good for patients who have shown improvement at discharge, while poor for patients who left against medical advice or died in the hospital. Logistic regression analysis was done to determine independent predictors for treatment outcome/in-hospital mortality using SPSS version 20 with statistical significant at \( P<.05 \).

RESULTS: Of 225 patients with DKA, 124 (55.1%) were male. Regular insulin was prescribed to all patients and antibiotics were administered to 87 (38.7%). Potassium supplementation was given only for 28 (12.4%). Non-adherence to insulin treatment (n = 91; 40.4%) and infection (n = 66; 29.3%) were the principal DKA precipitating factors. Even though 73.8% of hospitalized patients with DKA have shown good treatment outcomes, DKA contributed 12% in-hospital mortality. The result of multivariate logistic regression analysis shown that hypoglycemia is the only independent predictor for in-hospital mortality\( [P= .03] \). Moreover, the independent predictors for poor DKA treatment outcome were found to be smoker \( [P= .04] \), Urinary tract infection (UTI) relative to other co-morbid condition \( [P<.001] \), severe hypokalemia which increase risk of poor treatment outcome by around 4 times \( [P= .03] \), and use of Metronidazole as a concurrent medication relative to other concurrent medication \( [P=.03] \).

CONCLUSION: There was a high in-hospital mortality rate due to correctable causes. This mortality is unacceptable as it was majorly related to the poor practice of potassium supplementation and hypoglycemia due to insulin. Thus, clinicians and stakeholders should have to focus on modifiable factors (hypokalemia, UTI, and hypoglycemia) to reduce poor treatment outcome/in-hospital mortality.

KEYWORDS: Diabetic ketoacidosis, management, treatment, in-hospital mortality, Shashemene Referral Hospital, Ethiopia

RECEIVED: June 21, 2020. ACCEPTED: February 25, 2021.

DECLARATION OF CONFLICTING INTERESTS: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

CORRESPONDING AUTHOR: Gosaye Mekonen Tefera, Department of Pharmacy, Clinical Pharmacy Unit, Ambo University, Ambo, P.O. 19, Ethiopia.
Email: Gosi2010pharma@gmail.com

Introduction

Globally, the prevalence of diabetes mellitus (DM) has risen dramatically with approximately 5 million deaths in the last decade. DM contributed to 3% of admission to medical wards in Ethiopia due to acute complications. The acute complications of DM include Diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and treatment related-hypoglycemia.1-5 DKA is the most common and yet potentially a life-threatening acute complication of DM that progresses rapidly to life treating illness, thus, it requires immediate medical intervention. DKA is linked with unrestrained DM, which causes neurologic morbidity and death.6 It occurs primarily in patients with type 1 DM and under stressful conditions such as trauma, surgery, and/or infections it can also occur in type 2 DM.7 It is mainly explained by hyperglycemia, ketonemia, and acidemia that can be associated along with a rising counter-regulatory hormone including cortisol, glucagon, and epinephrine.8,9 Hence, patients with DKA presents with dehydration, weight loss, polyuria, polydipsia, vomiting, weakness, and change of mental status.10 DKA severity is categorized as mild, moderate, or severe based on the metabolic acidosis severity, that is, the blood pH, bicarbonate, ketones, and the existence of altered mental status.11 The most commonly used DKA diagnostic criteria are fasting plasma glucose greater than 250 mg/dL, arterial pH 7.3, serum bicarbonate less than or equal to 18 mEq/L, an anionic gap greater than 10, and urine dipstick ketone level \( ≥ 2.11 \).

The management of DKA includes fluid resuscitation or
reCURRENT reHYDRATION, electrolyte replacement, insulin therapy, and correction of exacerbating factors.\textsuperscript{6,7,12}

The prevalence of DKA in children and adolescents varies from 18.6\% to 43.9\% in developed countries such as Canada, United States, Australia, Italy, and France;\textsuperscript{13-18} whereas the overall mortality rate varies from 0.15\% to 0.3\% in developed countries. However, the mortality rate of children and adolescents with DKA is relatively high in developing countries that account for 3.4\% to 13.4\% including India, Bangladesh, and Pakistan.\textsuperscript{19} Similarly, the cause for mortality varies between developed and developing countries; for instance, cerebral edema is the predominant cause in developed countries while sepsis, shock, cerebral edema, and renal failure are the main causes with high incidences in developing countries.\textsuperscript{19}

While there has been a great improvement in the knowledge, epidemiology, and management of DKA conditions in the developed worlds, there has been reserved improvement in sub-Saharan Africa.\textsuperscript{20} Although DM is recognized as one of the health problems in developing countries like Ethiopia, there has been a little guarantee for the successful outcomes and its complications as the setup have not been well-documented.\textsuperscript{21}

There is a scarcity of data regarding DKA management practice, treatment outcomes/in-hospital mortality, and its predictors among hospitalized patients with DKA in Ethiopia. Thus, the scant information in the country is a barrier for both clinicians and policymakers, to promote better health service and prevent mortality due to DKA. Therefore, to fill the gaps this study was conducted to assess the DKA management, treatment outcomes/in-hospital mortality, and its predictors among hospitalized patients with DKA at the Medical ward of Shashemene Referral Hospital, Ethiopia.

Methods and Participants
A retrospective study was conducted from February 01 to 15, 2017 based on the cards of patients with DKA who were admitted from 01 February 2015 to 31 January 2017 to the Medical ward of Shashemene Referral Hospital (SRH), Ethiopia. SRH is located in the Oromia region, Kuyera town, and 238 km away to the south of Addis Ababa; the capital city of Ethiopia. Approximately, it provides service for 2.1 million people from the catchment area. The clinical records of all DM patients with \( \geq 15 \) years of age that were diagnosed to have DKA and admitted to the medical ward of SRH with complete information were included in the study. For patients with re-admission (more than 1 admission), the most recent admission data were considered for the study.

Single population proportion formula was used to determine the sample size with a 95\% confidence interval within a 5\% marginal error (\( W \)). \( N = 482 \) is the total number of patients with DKA admitted within the 2 years (February 01/2015 to January 31/2017). \( P \) is the proportion of DKA treatment outcome; we considered 50\% to maximize the sample size.

\[
n_1 = \frac{Z(\hat{P}/2)^2 \cdot P(1-P)}{W^2}
\]

\[
= 1.96^2 \times \frac{(0.5*0.5)}{0.05^2} = 384 \text{ for DKA treatment outcome}
\]

Since the sample was going to be taken from a relatively small population (<10000), then the sample size was adjusted as:

\[
n_f = \frac{n}{1 + \frac{n}{N}} = 214,
\]

\[
then 10\% for incomplete card was added = 236
\]

Where \( n_1 = \) the desired sample, \( n_f \) is the final sample size after adjustment. The card number of those DKA patients was identified first by checking the registration logbook manually for DKA diagnosis. Then using this logbook, the card number of 236 patients were selected for the study using systematic random sampling (every other card or 482/236 = 2) starting from the first register (relative to study inclusion period). A total sample size of 236 DKA patient’s card was reviewed for analysis, of these study participants’ cards, only 225 patient cards were included in the final analysis. The cards of DKA patients that had \( > 20\% \) incomplete data were excluded from the study. Thus, the cards of 9 patients were excluded due to incomplete data from the final analysis. The collected data includes socio-demographic characteristics, baseline clinical data, and DKA management information or medication-related information, and treatment outcome of DKA, using a checklist. This data was collected by 2 trained, fifth-year Pharmacy students.

Statistical analysis, operational definitions, and ethical clearance
The data were cleaned, coded, and entered into SPSS, then analyzed using SPSS version 20 software. To determine independent predictors of in-hospital mortality, binary logistic regression analysis results with \( P < .25 \) were entered into multivariate logistic regression. Then \( P \approx .05 \) was considered statistically significant.

The following operational definition was considered for the current study purpose. Good treatment outcome: those patients who showed improvement after treatment at discharge. Poor treatment outcome: those patients who left against medical advice or died in the hospital. Mild DKA: arterial pH level of 7.25 to 7.3 and serum bicarbonate level of 15 to 18 mEq/L. Moderate DKA: arterial pH level of 7.0 to 7.24 and serum bicarbonate level of 10 to 14.9 mEq/L. Severe DKA: arterial pH level of less than 7.0 and a serum bicarbonate level of less than 10 mEq/L. Hypoglycemia: Blood sugar of less than 70 mg/dL. Severe hypokalemia is a plasma potassium level of \(< 2.5 \text{ mmol/L} \).
Ethical clearance was obtained from the Ethical Review Board of Ambo University, College of Medicine, and Health Science with a referral number of phar/64/2009. Permission was sought from the medical director of SRH before reviewing the patient’s cards. Confidentiality of the information was assured and privacy was maintained. The ethical review board waived informed consent owing to the nature of the retrospective study design.

**Results**

**Socio-demographic characteristics of the study participants**

The study included 225 complete cards of DKA patients (95.3% response rate) with a mean ± SD age of 28.15 ± 12.9 years. The studied sample included 124 (55.1%) male and 101 (44.9%) female DKA patients. Based on the patient’s lifestyle, 71 (31.6%) were Khat (*Catha edulis*) chewers. Majority of the patients (n = 114, 50.7%) were Muslim and single (n = 126, 56%). The average weight of the patients in this study was 54 kg. Regarding the type of DM, the majority of study subjects (n = 141, 62.7%) had known type I with DKA followed by newly diagnosed type I DM with DKA (n = 56, 24.9%).

**Clinical characteristics and co-morbid conditions of the study participants**

Majority of the patients (n = 156; 69.3%) were admitted within 24 hours after DKA sign and symptom onset followed by 24 to 48 hours (n = 53; 23.6%). The median time from symptom onset to hospital admission was 24 hours. The most common clinical presentation reported were polyuria (n = 218; 96.9%), polydipsia (n = 208; 92.4%), and polyphagia (n = 87; 38.7%) (Table 1).

About 81 (36%) of the studied patients had no known documented precipitating factors of DKA in the patient’s chart while 144 (64%) of the patients had precipitating factors for DKA. The principal precipitating factor of DKA, as shown in Table 1, was non-adherence to insulin treatment (n = 91; 40.4%). Infection accounted for precipitating DKA in 66 (29.3%) cases. The median time from hospital admission to initiation of fluid and insulin therapy was half-hour and 1.5 hours, respectively. Of the 225 DKA patients, most (n = 130; 57.8%) of them were diagnosed as moderate followed by mild (n = 60; 26.6%) and severe DKA (n = 35; 15.6%).

Among 225 study participants, 99 (44%) of them have co-morbid and concurrent infections. Community-acquired pneumonia (n = 52; 23.1%) was identified as the major concurrent infection while hypertension (n = 23; 10.2%) was the major non-infectious co-morbid condition in the hospitalized DKA patients (Table 2).

### Table 1. Initial clinical presentation and precipitating factor for the development of DKA.

| CLINICAL PRESENTATION | FREQUENCY (%) | PRECIPITATING FACTORS | FREQUENCY (%) |
|-----------------------|---------------|-----------------------|---------------|
| Polyuria              | 218 (96.9)    | Non-adherence to insulin treatment | 91 (40.4) |
| Polydipsia            | 208 (92.4)    | Infection             | 66 (29.3)    |
| Polyphagia            | 87 (38.7)     | Others                | 13 (5.8)     |
| Generalized body weakness | 45 (20.0)    |                       |              |
| Weight loss           | 37 (16.4)     |                       |              |
| Loss of consciousness | 22 (9.8)      |                       |              |
| Vomiting              | 18 (8.0)      |                       |              |
| Abdominal pain        | 20 (8.9)      |                       |              |

### Table 2. Co-morbid disease and concurrent infections/complication identified in hospitalized DKA patients and anti-diabetic medications prescribed during hospital discharge.

| CO-MORBID DISEASE AND CONCURRENT INFECTIONS/COMPLICATION | FREQUENCY (%) |
|---------------------------------------------------------|---------------|
| Community-acquired pneumonia                           | 52 (23.1)     |
| Hypertension                                           | 23 (10.2)     |
| Urinary tract infection                                | 9 (4.0)       |
| Diabetic foot ulcer                                    | 6 (2.7)       |
| Others                                                 | 9 (4.0)       |

Anti-diabetic medications used for the treatment of type 1 and 2 diabetes

- RI + NPH 0.5 units/kg/day BID 102 (45.3)
- Metformin 500 mg PO BID 8 (3.6)
- Glibenclamide 5 mg PO daily 3 (1.3)
- Metformin 500 mg PO BID + Glibenclamide 5 mg PO daily 9 (4.0)
- NPH 0.5 units/kg/day BID 44 (19.6)

Abbreviations: BID, bis in die or twice a day; KG, kilogram; NPH, neutral protamine hagedom, it is intermediate-acting insulin; PO, per os or peroral; RI, regular insulin, it is short-acting insulin.
Management of hospitalized DKA patients

Insulin therapy was administered to all patients. All the DKA patients (n = 225; 100%) received Regular insulin (RI) 10 units IV and 10 units IM stat at time of admission while 95 (42.2%) and 130 (57.8%) DKA patients were administered RI 5 units subcutaneous every hour and RI 0.1 units per kg per hour, respectively until urine becomes free of the ketone. Then, RI 4 to 16 units IV (n = 177; 78.7%) were given every 5 hours during the sliding scale. Modified insulin therapy was also administered including RI + NPH 0.5 units/kg/day (n = 188; 83.6%) and NPH 0.5 units/kg/day (n = 37; 16.4%) BID until discharged.

The most commonly used fluid replacement per hospital stay was 0.9% normal saline solution, which accounts for 178 (79.1%) and administered for those patients with blood glucose levels greater than 250 mg/dL. On the other hand, 5% dextrose in 0.9% normal saline was administered to those DKA patients whose blood glucose level is below 250 mg/dL (n = 28; 12%). The median amount of fluid replacement was 5 L per hospital stay. Potassium supplementation was given only for 28 (12.4%) patients in the form of KCl injection (n = 19; 8.4%) and tablet (n = 9; 4.0%) and supplementation was not prescribed for 197 (87.6%) patients.

Among the studied hospitalized DKA patients, only 166 (73.8%) were discharged with insulin and oral hypoglycemic agent. Among these, 45.3% were discharged with RI + NPH and 4% were metformin and glibenclamide (Table 2).

About 126 DKA patients (56%) had no concurrent medication. Out of the total concurrent medication prescribed, 32.9% of patients prescribed antibiotics followed by Angiotensin-converting enzyme (ACE) inhibitors 12% (Table 3).

### Table 3. Concomitantly used medications for DKA patients in-hospital.

| TYPE OF CONCURRENTLY USED DRUGS IN MEDICAL WARD | FREQUENCY (%) |
|-----------------------------------------------|---------------|
| ACE inhibitors                                | 27 (12.0)     |
| Antibiotics                                   | 36 (16.0)     |
| Ceftriaxone 1 gm IV BID and Azithromycin 500 mg| 27 (12.0)     |
| Ceftriaxone 500 mg IV BID                      | 11 (4.9)      |
| Metronidazole 500 mg IV TID                    | 9 (4.0)       |
| Others                                        |               |

Abbreviations: BID, bis in die or twice a day; IV, intravenous; TID, ter in die or 3 times a day.

Treatment outcome and its predictors for hospitalized patients with DKA

About 166 (73.8%) hospitalized DKA patients have shown an improved treatment outcome (good treatment outcome) at discharge, while 59 (26.2%) patients have shown a poor treatment outcome. Out of the patients with poor treatment outcomes, 32 (14.2%) were left against medical advice and in-hospital mortality was 27/225 (12%). Among the known causes of in-hospital mortality as recorded on the patients’ card, severe hypokalemia (n = 14; 52%), hypoglycemia secondary to increased insulin dose (n = 7; 26%), and worsening of DKA (n = 6; 22%) as the result of the co-morbid condition were the most common reason. However, the result of multivariate logistic regression analysis shown that hypoglycemia was the only independent predictor for in-hospital mortality [P = .03]. Moreover, the independent predictors for poor DKA treatment outcome were found to be smoker [P = .04], Urinary tract infection (UTI) relative to other co-morbid conditions [P < .001]. Severe hypokalemia which increase risk of poor treatment outcome by around 4 times [P = .02], and use of Metronidazole as a concurrent medication relative to other concurrent medication [P = .03], (Table 4).

Discussion

The 2-year hospital-based retrospective study found that mortality due to DKA in SRH was high, which needs urgent attention from stakeholders. Especially in the 21st century, the death of DKA patients due to preventable causes like hypokalemia and hypoglycemia is unacceptable. Because mortality due to DKA in developed countries was almost less than 1%. However, in developing countries including Ethiopia, mortality is high due to different reasons.23,24 However, the mortality rate in Kenya was even higher than the current study report (29.8%).22,23 This finding was consistent with the studies conducted at St Luke’s Hospital (Ethiopia) and Jimma University Specialized Hospital (Ethiopia).21,23

Even though DKA is a potentially life-threatening diabetic complication, it is exclusively preventable. But in the current study, it was more prevalent due to different reasons.23,24 The most common precipitating factors for DKA in this study were non-adherence to insulin treatment and infection.23,25 Pneumonia was identified as the major concurrent infection. This finding was inconsistent with the study conducted at the University of Malaysia in which hypertension was responsible for 54.5%.25 The low prevalence of hypertension could be explained partly due to the difference in mean age (28.15 ± 12.9) of the patients as aging is linked to hypertension.

Insulin therapy was generally administered according to Ethiopian Standard Treatment Guidelines for DKA management.26 The dose could possibly depend on the physicians’
Table 4. Predictors for treatment outcome and in-hospital mortality for DKA patients.

| VARIABLES         | CATEGORIES     | TREATMENT OUTCOME OF DKA | CRUDE ODD RATIO (95% C.I) | ADJUSTED ODD RATIO (95% C.I) | P-VALUE |
|-------------------|----------------|--------------------------|---------------------------|-------------------------------|---------|
|                   |                | GOOD (N = 166) (%)        | POOR# (N = 59) (%)        |                               |         |
| Age               | 16-20          | 68 (76)                  | 21 (24)                   | 1.8 (0.4, 8.7)                | 0.59    |
|                   | 21-25          | 32 (70)                  | 14 (30)                   | 1.4 (0.3, 7.6)                | 0.84    |
|                   | 26-35          | 27 (73)                  | 10 (27)                   | 1.5 (0.3, 8.0)                | 0.74    |
|                   | 36-50          | 35 (83)                  | 7 (17)                    | 1.8 (0.3, 10.0)               | 0.91    |
|                   | Above 50       | 4 (36)                   | 7 (74)                    | 1                              | 1       |
| Sex               | Male           | 87 (70)                  | 37 (30)                   | 0.8 (0.4, 1.4)                | 0.31    |
|                   | Female         | 79 (77)                  | 24 (23)                   | 1                              | 1       |
| Social            | Chat chewers   | 61 (86)                  | 10 (14)                   | 1.0 (0.3, 3.5)                | 0.76    |
| history           | Smokers        | 10 (71)                  | 4 (29)                    | 0.1 (0.01, 1.5)               | 0.04*   |
|                   | Unknown        | 87 (67)                  | 40 (33)                   | 0.6 (0.2, 2.3)                | 0.28    |
|                   | Others         | 8 (67)                   | 4 (33)                    | 1                              | 1       |
| Marital status    | Single         | 94 (75)                  | 32 (25)                   | 0.9 (0.5, 1.7)                | 0.65    |
|                   | Married        | 72 (73)                  | 27 (27)                   | 1                              | 1       |
| Occupation        | Student        | 65 (68)                  | 31 (32)                   | 0.6 (0.2, 1.4)                | 0.55    |
|                   | Farmer         | 55 (81)                  | 13 (19)                   | 0.6 (0.2, 1.5)                | 0.53    |
|                   | Employed       | 26 (87)                  | 4 (13)                    | 0.8 (0.3, 2.3)                | 0.73    |
|                   | Others         | 20 (61)                  | 11 (39)                   | 1                              | 1       |
| DM type           | Known type I with DKA | 118 (84)                  | 23 (16)                   | 0.9 (0.4, 2.3)                | 0.95    |
|                   | Newly diagnosed type I with DKA | 36 (64)                  | 20 (36)                   | 0.8 (0.3, 2.1)                | 1.00    |
|                   | Known type II with DKA | 15 (54)                  | 13 (46)                   | 1                              | 1       |
| Co-morbidity      | Pneumonia      | 52 (63)                  | 31 (37)                   | 0.4 (0.2, 1.0)                | 0.39    |
|                   | Hypertension   | 23 (77)                  | 7 (23)                    | 2.5 (1.0, 6.2)                | 0.19    |
|                   | UTI            | 9 (90)                   | 1 (10)                    | 0.8 (0.2, 3.9)                | 0.00*   |
|                   | Others         | 9 (100)                  | 0 (0)                     | 1                              | 1       |
| Potassium status  | Severe hypokalemia | 26 (93)                  | 2 (7)                     | 0.4 (0.2, 0.8)*               | 0.02*   |
|                   | Not severe/unknown result | 167 (85)                  | 30 (15)                   | 1                              | 1       |
| Fluid therapy     | 0.9%NS         | 142 (80)                 | 36 (20)                   | 0.6 (0.2, 1.6)                | 0.39    |
|                   | D5%W           | 12 (44)                  | 15 (66)                   | 0.8 (0.2, 2.7)                | 0.69    |
|                   | DNS            | 12 (60)                  | 8 (40)                    | 1                              | 1       |
| Drug for co-morbidity | Ceftriaxone + Azithromycin | 31 (86)                  | 5 (14)                    | 0.5 (0.19, 1.5)               | 0.63    |
|                   | Ceftriaxone    | 25 (93)                  | 2 (7)                     | 0.9 (0.3, 2.4)                | 0.70    |
|                   | Enalapril      | 20 (74)                  | 7 (26)                    | 2.5 (1.0, 6.6)                | 0.92    |
|                   | Metronidazole  | 8 (67)                   | 4 (33)                    | 6.1 (1.5, 26.0)*              | 0.00*   |
|                   | Other medication | 9 (100)                  | 0 (0)                     | 1                              | 1       |
| Residence         | Urban          | 118 (76)                 | 37 (24)                   | 0.7 (0.4, 1.2)                | 0.28    |
|                   | Rural          | 48 (69)                  | 22 (31)                   | 1                              | 1       |

(Continued)
Table 4. (Continued)

| VARIABLE               | CATEGORIES | IN-HOSPITAL MORTALITY | CRUDE ODDS RATIO (95% C.I) | ADJUSTED ODDS RATIO (95% C.I) | P-VALUE |
|------------------------|------------|------------------------|----------------------------|-------------------------------|---------|
| Reason for in-hospital mortality | Hypokalemia | No (N=198) (%)          | Yes (N=27) (%)              | 0.2 (0.1, 1.5)                | 4.8 (0.6, 41.2) | 0.16   |
|                        |            |                        |                            |                               |         |
|                        | Hypoglycemia | 13 (48)                | 14 (52)                    | 0.2 (0.1, 1.5)                | 4.8 (0.6, 41.2) | 0.16   |
|                        | Worsening of DKA | 20 (74)                | 7 (26)                     | 6.8 (1.3, 36.1)*              | 0.1 (0.2, 0.8) | 0.03** |

Abbreviations: C.I, confidence interval; DKA, diabetic keto acidosis; DM, diabetes mellitus; DNS, dextrose in normal saline; D5%W, 5% dextrose; LAMA, left against medical advice; #(LAMA = 32 and death = 27); 0.9%Ns, 0.9% normal saline; UTI, urinary tract infection.

*Significantly associated with treatment outcomes.
**Significantly associated with in-hospital mortality.

concerns about the patients either hypoglycemia or rapid reduction of blood glucose levels. Even though no routine blood chemistry machine for plasma electrolyte study to determine the level of serum potassium as one important DKA treatment protocol in the study area, potassium supplementation was given only for a few patients. This is an indicator of the inappropriate DKA patient management in this hospital. This result was partially supported by the study from St Lukes Hospital, Malta [Ethiopia].21 This condition brought a risk of incorrect use of medication for DKA patients which require urgent intervention to save the life of patients. Because almost all of the patients need potassium supplementation, due to Insulin or acidosis induced potassium exchange between extracellular and intracellular.27 Indeed, study confirmed that around 22.7% of DKA patients at admission present with hypokalemia,23 thus, the addition of insulin therapy will exacerbate the condition to be in more severe hypokalemia.26,29 In addition, a study from the UK confirmed that patients treated for DKA had hypoglycemia in 27.6% and hypokalemia in 55%.28 Moreover, supplementation of potassium in the absence of serum potassium may lead to death as a result of hyperkalemia or cardiac complication.29

Thus, the higher in-hospital mortality rate in our setting and other parts of the world is the issue that needs urgent attention to improve the quality of DKA care.12,24,25,30-32 The most probable reason for such a high mortality rate could be due to lack of appropriate diabetic care, lack of screening for hypoglycemia and hypokalemia, financial constraints for laboratory support and insulin, as well as poor management practice of co-morbidity treatment like hypokalemia and hypoglycemia.27-29 Therefore, in developing countries like Ethiopia, there should be free health care for those patients with DM to improve access to quality care.

The current study has shown that hypoglycemia is the only independent predictor for in-hospital mortality. Moreover, the independent predictors for poor DKA treatment outcomes were found to be smokers, UTI, and severe hypokalemia. Similar to this study finding, the studies have shown that the presence of hypokalemia,33 and presence of infection/fever/sepsis,22,24 were predictors of negative DKA treatment outcome.31 This study was not without limitations. The first one is the nature of the study design (retrospective) and the second was a single-center study, which may not be representative of the whole DKA patients in Ethiopia. The final limitation was unavailability of routine electrolyte test in the hospital.

Conclusion and Recommendation

There was a high in-hospital mortality rate due to correctable causes. DKA management protocol specifically Insulin therapy was generally administered according to Ethiopian Standard Treatment Guideline. However, the high in-hospital mortality is unacceptable as it was majorly related to the poor practice of serum potassium assessment as well as potassium supplementation and hypoglycemia secondary to the increased insulin dose. Given that these factors are easily preventable, healthcare providers, government of Ethiopia, and stakeholders should set an emphasis on adherence to standard DKA treatment protocol, availability of serum potassium test, routine blood sugar test to avoid hypoglycemia, and insulin to improve adherence, so that we can reduce in-hospital mortality due to DKA.

Acknowledgements

We would like to thank the data collectors and the staff of Shashemene Referral Hospital who assisted and allowed us to collect the necessary data from the hospital.

Author Contributions

Taye GM: conceived the study, participated in its design. AJ and Taye GM: Did the data collection and statistical analysis. FA and Tefera GM: contributed to study design, data collection, and statistical analysis. MHB, Tefera GM, Taye GM, and AJ: contributed to the drafting of the manuscript, study design, and statistical analysis. All authors read and approved the final manuscript.

ORCID iDs

Getu Melesie Taye [15] https://orcid.org/0000-0002-9870-4211
Gosaye Mekonen Tëfera [15] https://orcid.org/0000-0002-7534-2828
REFERENCES

1. WHO. Global report on diabetes. Geneva, Switzerland. 2016. http://www.who.intiris/handle/10665/204871
2. International Diabetes Federation. IDF Diabetes Atlas. 8th ed. International Diabetes Federation, 2017.
3. Feleky Y, Enquelles F. An assessment of the health care system for diabetes in Addis Ababa, Ethiopia. Ethiop J Health Dev. 2005;19:203-210.
4. Powers AC. Diabetes Mellitus. In Harrison's Principles of Internal Medicine.19th ed. The McGraw-Hill Companies, 2015, pp. 2275-2304.
5. Corwell B, Knight B, Olivieri L, Willis GC. Current diagnosis and treatment of hyperglycemic emergencies. Emerg Med Clin. 2014;32:437-452.
6. Gosmanov AR, Gosmanova EO, Dillard-Cannon E. Management of adult diabetic ketoacidosis. Diabetes Metab Syndr Obes. 2014; 7:255-264.
7. Hamed ZS, Gawaly AM, Abbas KM, El Ahwal LM. Epidemiology of infection as a precipitating factor for diabetic ketoacidosis at Tanta University Hospital. Tanta Med J. 2017;45(2):68.
8. Savage MW, Dhatairya KK, Kilvert A, et al. Diabetes UK position statements and care recommendations/joint British diabetes societies guideline for the management of diabetic ketoacidosis. Diabetes Metab. 2011;28:908-915.
9. Kitarichi AE, Umpierrez GE, Miles JM, Fisher JN. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335-1343.
10. Kitarichi AE, Umpierrez GE, Murphy MB, et al. Management of hyperglycemic crises in patients with diabetes. Diabetes Care. 2001;24:131-153.
11. Aloueri Z, Honnai H. Precipitating factors, outcomes, and recurrence of diabetic ketoacidosis at a university hospital in Damascus. Avicenna J Med. 2015;5:11-15.
12. Choleau C, Maitre J, Pierucci AF, et al. Ketoacidosis at diagnosis of type 1 diabetes in French children and adolescents. Diabet Metab. 2014;40:137-142.
13. Zuccolini S, Scaravuzzi AE, Bonfanti R, et al. A multicenter retrospective survey regarding diabetic ketoacidosis management in Italian children with type 1 diabetes. J Diabetes Res. 2016;2016:5719470.
14. Fitrich M, Schober E, Rumi-Merhar B, et al. Diabetic ketoacidosis at diagnosis in Austrian children: a population-based analysis, 1989-2011. J Pediatr. 2013;163:1484-1488.
15. Klingensmith GJ, Tamborlane WV, Wood J, et al. Diabetic ketoacidosis at diabetes onset: still an all too common threat in youth. J Pediatr. 2013;162:330-334.
16. Malik FS, Hall M, Mangione-Smith R, et al. Patient characteristics associated with differences in admission frequency for diabetic ketoacidosis in United States Children’s Hospitals. J Pediatr. 2016;171:104-110.
17. Bui H, To T, Stein R, Fung K, Daneman D. Is diabetic ketoacidosis at disease onset a result of missed diagnosis? J Pediatr. 2015;166:472-477.
18. Poovazhagi V. Risk factors for mortality in children with diabetic ketoacidosis from developing countries. World J Diabetes. 2014;5:932-938.
19. Majaliwa ES, Elouiyen BJ, Adesiyun OO, Laigong P. Type 1 diabetes mellitus in the African population: epidemiology and management challenges. Acta BioMed. 2009; 79(3):255-259.
20. Ottino CT, Kayima JK, Omonge EO, Oyoo GO. Diabetic ketoacidosis: risk factors, mechanism and management strategies in sub-Saharan Africa: a review. East Afr Med J. 2005;82:S197-S203.
21. Abela AG, Magri CJ, Debono M, Calleja N, Vassallo J, Azzopardi J. An audit of the management of diabetic ketoacidosis at St Luke’s Hospital. Malta Med J. 2008;20:16-21.
22. Ottino CT, Kayima JK, Mbugua PK, Amayo AA, Mligioye SO. Prognostic factors in patients hospitalised with diabetic ketoacidosis at Kenyatta National Hospital, Nairobi. East Afr Med J. 2010;87:67-74.
23. Desse TA, Ezohie TC, Godina EK. Predictors and treatment outcome of hyperglycemic emergencies at Jimma University Specialized Hospital, southwest Ethiopia. BMC Res Notes. 2015;8:53.
24. Iddi S, Francis B, Jaka HM, Mirabindo MM, Mushi MF. Clinical presentation and precipitating factors of diabetic ketoacidosis among patients admitted to intensive care unit at a tertiary hospital in Mwanza, Tanzania. Tanzan J Health Res. 2017;19:1-5.
25. Usman A, Sulaiman SA, Khan AH, Adnan AS. Profiles of diabetic ketoacidosis in multiracial diabetic population of Malaysia. Trop J Pharm Res. 2015;14:179-185.
26. FMHACA of Ethiopia. Standard Treatment Guidelines for General Hospitals. 3rd ed. Food, Medicine, Health Care Administration and Control Authority, 2014, pp. 77-80.
27. Usman A, Makmor Bakry M, Mustafa N, et al. Correlation of acidosis-adjusted potassium level and cardiovascular outcomes in diabetic ketoacidosis: a systematic review. Diabetes Metab Syndr Obes. 2019;12:1323-1338.
28. Dhatariya K, Kunney I, Higgins K, Sampson M, Iceton G. National survey of the management of diabetic ketoacidosis (DKA) in the UK in 2014. Diabet Med. 2016;33:252-260.
29. Usman A. Initial potassium replacement in diabetic ketoacidosis: the unnoticed area of gap. Front Endocrinol. 2018;9:109.
30. Niaa ZA, Razaq A, Chaudhary UJ, et al. Mortality review of diabetic ketoacidosis in Mayo Hospital, Lahore-Pakistan. Biomedica. 2005;21:83-85.
31. Zargar AH, Wani AI, Massodi SR, et al. Causes of mortality in diabetes mellitus: data from a tertiary teaching hospital in India. Postgrad Med J. 2009;85:227-232.
32. Anthanont P, Khawcharoenporn T, Tharavanij T. Incidences and outcomes of hyperglycemic crises: a 5-year study in a tertiary care center in Thailand. J Med Assoc Thai. 2012;95:995.
33. Pandya T, Sekhon R, Ghazarian Z, Lubhan M, Hanna M, Khan MA. Mortality predictors in patients with diabetic ketoacidosis and respiratory failure. B46 critical care: ICU epidemiology and outcomes. American thoracic society. Am J Respir Crit Care Med. 2016;193:A3646.
34. Efthathiou SP, Tsikous AG, Tsoulos DI, et al. A mortality prediction model in diabetic ketoacidosis. Clin Endocrinol. 2002;57:595-601.